Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Vanda Pharmaceuticals Inc (NASDAQ:VNDA)

During the Trading Day
7.84 -0.15 / -1.88%
As of 4:00pm ET
Day’s Change
During After-Hours   Switch to standard view »
7.84 0.00 / 0.00%
Volume: 854.00
Health Technology

Company Description

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. Its product portfolio includes Fanapt and Tasimelteon. The Fanapt product is a compound for the treatment of schizophrenia, the oral formulation of, which is currently being marketed and sold in the U.S. by Novartis. The Tasimelteon product is a compound for the treatment of sleep and mood disorders, including circadian rhythm sleep disorders, which is currently in clinical development. Vanda Pharmaceuticals was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Contact Information

Vanda Pharmaceuticals, Inc.
2200 Pennsylvania Avenue NW
Washington District Of Columbia 20037
P:(202) 734-3400
Investor Relations:
(202) 734-3428



Other institutional90.43%
Individual stakeholders43.25%
Mutual fund holders20.20%

Top Executives

Mihael Hristos PolymeropoulosPresident, Chief Executive Officer & Director
James Patrick KellyChief Financial Officer, Treasurer & Senior VP
Paolo BaroldiChief Medical Officer & Senior Vice President
Gian ReverberiChief Commercial Officer & Senior Vice President
Richard L. GulinoSecretary, General Counsel & Senior VP